当前位置: 首页  > 股票分析 > 港股分析

CStone Pharmaceuticals (2616 HK) - Delivering on numerous catalysts

2019/6/6 6:10:32 来源:招商证券 作者: 人评论

作者:Su Zhang,Sam HU,Hayden Zhang,Marcella Cheung时光:2019年06月05日重要性:普通报告行业评级:公司评级:相干股票代码:浏览权限: 该文章钻石卡、金卡、银卡客户可浏览全文摘要:Report title:CStone Pharmaceuticals (2616 HK) - Delivering on numerous cata…

作者: Su Zhang,Sam HU,Hayden Zhang,Marcella Cheung
时光: 2019年06月05日
重要性: 普通报告
行业评级:
公司评级:
相干股票代码:
浏览权限:   该文章钻石卡、金卡、银卡客户可浏览全文
摘要: Report title:CStone Pharmaceuticals (2616 HK) - Delivering on numerous catalysts
Analyst:Su Zhang,Sam HU,Hayden Zhang,Marcella Cheung
Report type:Company
Date:20190605
[Summary]

■ CStone’s partner Blueprint updated BLU-667 in NSCLC and thyroid cancer, and avapritinib (BLU-285) in gastrointestinal stromal tumors (GIST) at ASCO 2019, showing good progress
■ Ivosidenib (TIBSOVO) is filed NDA for the treatment of r/r AML in Taiwan, marking the start of commercialization of CStone’s assets
■ Maintain BUY on the delivery of numerous catalysts

BLU-667 and avapritinib demonstrated potent antitumor effect
Blueprint presented updated data of BLU-667 from the global ARROW study (NCT03037385) at ASCO 2019 regarding RET-fusion+ NSCLC and RET-altered thyroid cancers by oral and poster presentation, respectively. ORR for RET fusion+ NSCLC,MTC and PTC are 56%, 47% and 50%, respectively. Clinical data of avapritinib in 4L+ and PDGFRa Exon 18 GIST from NAVIGATOR study (NCT02508532) were also updated in ASCO. ORR for PDGFRa Exon 18 GIST and 4L+ GIST were 86% and 22%. We believe both BLU-667 and avapritinib exhibit quite solid efficacy data in ASCO this year, which may facilitate their launch process and catalyse their NDA in China.
CStone submitted NDA for TIBSOVO treating r/r AML in Taiwan
A NDA for TIBSOVO for the treatment of r/r AML has been submitted to the Taiwan Food and Drug Administration (TFDA) as the first to-be-approved treatment of CStone. As a first-in-class inhibitor of the mutant isocitrate dehydrogenase-1 (IDH1m inhibitor), TIBSOVO was granted approval from the U.S. FDA for treating r/r AML in July 2018 based on a Phase I study results (n=174), including rate and duration of CR and CR with partial hematologic recovery (CRh), and this NDA filing in Taiwan is very likely to become the first approved treatments for AML patients with IDH1m in the Greater China Area.
Updates from CS1001-101 trial in ASCO 2019
CStone also presented the updated data from the CS1001-101 trial at ASCO 2019 in a poster presentation (Phase Ia/Ib, NCT03312842). Anti-tumor efficacy and safety of CS1001 in patients with advanced solid tumors or lymphomas were similar to those in previous preliminary analysis.
Maintain BUY on the delivery of numerous catalysts
We believe Blueprint’s small molecules demonstrating promising clinical data will accelerate CStone’s NDA in China. Considering the small market size of IDH1m inhibitor in Taiwan, we maintain BUY rating and rNPV-based TP at HK$19.83.

[投资评级界说]

公司短期评级

以报告日起6个月内,公司股价相对同期市场基准(沪深300指数)的表示为尺度:激烈引荐:公司股价涨幅超基准指数20%以上
谨慎引荐:公司股价涨幅超基准指数5-20%之间
中性:公司股价更改幅度相对基准指数介于±5%之间
回避:公司股价表示弱于基准指数5%以上

公司长期评级
A:公司长期竞争力高于行业均匀程度
B:公司长期竞争力与行业均匀程度分歧
C:公司长期竞争力低于行业均匀程度

[重要声明]
报告中的内容和看法仅供参考,并不组成对所述证券买卖的出价,在任何情形下,本报告中的信息或所表述的看法并不组成对任何人的投资建议。

相关资讯

    暂无相关的数据...

共有条评论 网友评论

验证码: 看不清楚?